Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 12, 2005, Pages 1071-1078

  Tsuzuki, Hideaki ^a   Sunaga, Hiroshi ^a   Ito, Toshihisa ^a   Narita, Norihiko ^a   Sugimoto, Chizuru ^a   Fujieda, Shigeharu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNA REPAIR; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MOUTH CARCINOMA; ONCOGENE C FOS; OROPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY;

AGED; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; THYMIDINE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 29144432312     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.131.12.1071     Document Type: Article

References (65)

1. Tsuzuki H, Fujieda S, Sunaga H, Noda I, Saito H. Expression of granulocyte colonystimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma. Cancer Res. 1998;58:794-800.
2. Fujieda S, Lee K, Sunaga H, et al. Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer. 1999;85:1439-1445.
3. Fujieda S, Sunaga H, Tsuzuki H, Fan GH, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 1999;136:1-9.
4. Fujieda S, Sunaga H, Tsuzuki H, Tanaka N, Saito H. Expression of plateletderived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin Cancer Res. 1998;4:1583-1590.
5. Fujieda S, Inuzuka M, Tanaka N, et al. Expression of p27 is associated with BAX expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer. 1999;84:315-320.
6. Fan GK, Fujieda S, Sunaga H, Tsuzuki H, Ito N, Saito H. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope. 1999;109:815-820.
7. Tsuzuki H, Fujieda S, Sunaga H, Narita N, Tokuriki M, Saito H. Expression of p27 and apoptosis in oral leukoplakia. Anticancer Res. 2003;23:1265-1270.
8. Ito T, Fujieda S, Tsuzuki H, et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 1999;140:81-91.
9. Fujieda S, Sunaga H, Tsuzuki H, et al. Expression of Fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer Lett. 2000;161:73-81.
10. Tsuzuki H, Fujieda S, Sunaga H, Sugimoto C, Tanaka N, Saito H. Expression of multidrug resistance-associated protein (MRP) in head and neck squamous cell carcinoma. Cancer Lett. 1998;126:89-95.
11. Fujieda S, Sugimoto C, Seki M, Sunaga H, Saito H. CD40 stimulation inhibits cell growth and Fas-mediated apoptosis in a thyroid cancer cell line. Oncol Res. 1998;10:433-439.
12. Kimura Y, Fujieda S, Takabayashi T, Tanaka T, Sugimoto C, Saito H. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett. 2000;155:163-168.
13. Fujieda S, Tanaka N, Sunaga H, et al. Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma. Cancer Lett. 1998;132:37-44.
14. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A. 1985;82:1526-1530.
15. Tachibana M, Miyakawa A, Tazaki H, et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res. 1995;55:3438-3443.
16. Mueller MM, Fusenig NE. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer. 1999;83:780-789.
17. Kato I, Katagiri W, Moriyama T, et al. G-CSFR expression as prognosticindicator for in patients with oral squamous cell carcinoma. In: Final program and abstract book of the 5th International Conference on Head and Neck Cancer; July 29-August 2, 2000; San Francisco, Calif. Abstract 144.
18. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science. 1990;250:830-832.
19. Gorelik E, Edwards RP, Feng X, et al. IL-12 receptor-mediated upregulation of FasL in human ovarian carcinoma cells. Int J Cancer. 2004;112:620-627.
20. Miyazono K, Okabe T, Urabe A, Takakuk F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem. 1987;262:4098-4103.
21. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338:557-562.
22. Haraguchi M, Miyadera K, Uemura K, et al. Angiogenic activity of enzymes. Nature. 1994;368:198.
23. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 1995;64:79-82.
24. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88:1110-1117.
25. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663-2674.
26. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74.
27. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347.
28. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
29. Drappa J, Brot N, Elkon KB. The Fas protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupusprone strain, MRL lpr/lpr. Proc Natl Acad Sci U S A. 1993;90:10340-10344.
30. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
31. Sassone-Corsi P, Verma IM. Modulation of c-fos gene transcription by negative and positive cellular factors. Nature. 1987;326:507-510.
32. Keath EJ, Caimi PG, Cole MD. Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals. Cell. 1984;39:339-348.
33. Krishnamachary N, Center MS. The MRP gene associated with a non-Pglycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993;53:3658-3661.
34. Steeg PS, Cohn KH, Leone A. Tumor metastasis and nm23: current concepts. Cancer Cells. 1991;3:257-262.
35. Hennessy C, Henry JA, May FE, Westley BR, Angus B, Lennard TW. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst. 1991;83:281-285.
36. Kluth B, Hess S, Engelmann H, Schafnitzel S, Riethmuller G, Feucht HE. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 1997;57:891-899.
37. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70-72.
38. Qin C, Wilson C, Blancher C, Taylor M, Safe S, Harris AL. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res. 2001;7:818-823.
39. Lo Muzio L, Leonardi R, Mariggio MA, et al. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma. Histol Histopathol. 2004;19:119-128.
40. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003;105:484-490.
41. Taubert HW, Bartel F, Kappler M, et al. Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer. 2003;97:2273-2278.
42. Sobin LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumours. 5th ed. Baltimore, Md: Wiley-Liss; 1997.
43. Sugimoto C, Fujieda S, Seki M, et al. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer. 1999;82:860-867.
44. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
45. Alcalde RE, Terakado N, Otsuki K, et al. Angiogenesis and expression of platelet-derived endotherial cell growth factor in oral squamous cell carcinoma. Oncology. 1997;54:324-328.
46. Mineta H, Miura K, Suzuki I, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer. 1999;85:1011-1017.
47. Xie X, Clausen OPF, Angelis PD, et al. The prognostic value of spontaneous apoptosis, bax, bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer. 1999;86:913-920.
48. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385:637-640.
49. Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991;64:425-427.
50. Griffiths L, Stratford IJ. The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumorigenicity, tumor growth, and oxygenation. Int J Radiat Oncol Biol Phys. 1998;42:877-883.
51. Kitazono M, Takebayashi Y, Ishitsuka K, et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun. 1998;253:797-803.
52. Igawa H, Fujieda S, Kimura Y, et al. Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) on the cell cycle in head and neck squamous cell carcinoma in vitro. Oncol Rep. 2003;10:967-971.
53. Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and potential for exploitation in cancer therapy. Br J Cancer. 1996;74:126-132.
54. Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res. 2000;6:381-389.
55. Giatromanolaki A, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL, Fountzilas G. Angiogenesis vs response after combined chemoradiotherapy of squamous cell head and neck cancer. Int J Cancer. 1999;80:810-817.
56. Fukuiwa T, Takebayashi Y, Akiba S, et al. Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics. Cancer. 1999;85:960-969.
57. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995;55:510-513.
58. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol. 1999;155:1557-1567.
59. Thacker JD, Dedhar S, Hogge DE. The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. Int J Cancer. 1994;56:236-243.
60. Sugimoto C, Fujieda S, Sunaga H, et al. Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates the type IV collagenase activity in head and neck cancer cells. Int J Cancer. 2001;93:42-46.
61. Noda I, Fujieda S, Ohtsubo T, et al. Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer. 1999;80:78-84.
62. Kaushansky K, Lin N, Adamson JW. Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors: mechanism for the hematopoietic response to inflammation. J Clin Invest. 1988;81:92-97.
63. Vancheri C, Ohtoshi T, Cox G, et al. Neutrophilic differentiation induced by human upper airway fibroblast-derived granulocyte/macrophage colonystimulating factor (GM-CSF). Am J Respir Cell Mol Biol. 1991;4:11-17.
64. Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest. 1991;87:986-995.
65. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Int J Cancer. 1999;80:868-874.